Apealea

RSS

paclitaxel

Authorised
This medicine is authorised for use in the European Union.

Overview

Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).

Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment.

Apealea contains the active substance paclitaxel.

This EPAR was last updated on 18/09/2023

Authorisation details

Product details
Name
Apealea
Agency product number
EMEA/H/C/004154
Active substance
paclitaxel
International non-proprietary name (INN) or common name
paclitaxel
Therapeutic area (MeSH)
Ovarian Neoplasms
Anatomical therapeutic chemical (ATC) code
L01CD01
Publication details
Marketing-authorisation holder
Inceptua AB
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
20/11/2018
Contact address

Gustavslundsv. 143
16751 Bromma
Sweden

Product information

11/09/2023 Apealea - EMEA/H/C/004154 - R/0017

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Antineoplastic agents

  • Taxanes

Therapeutic indication

Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
9 ratings
1 rating
1 rating